Overview

A Double-Blind Placebo Controlled Study To Determine the Optimal Immunopharmacological Dose Level of Isoprinosine in Immunodepressed Volunteers

Status:
Completed

Trial end date:
1969-12-31

Target enrollment:

Participant gender:

Summary

The objective of this double-blind placebo-controlled study is to evaluate the effect of Isoprinosine in a group of homogenous male volunteers who present with immunologic defects relative to: - Comparison of total helper and suppressor T-cell number between the groups. - Comparison of the phytohemagglutinins (PHA) and concanavalin A lymphoproliferative response and natural killer (NK) cell activity between the groups. - Determination of the clinical course of the volunteers after discontinuance of Isoprinosine.

Phase:

N/A

Details

Lead Sponsor:

Newport Pharmaceuticals International

Treatments:

Inosine Pranobex